Valbiotis announces the first patient first visit in the international phase ii/iii reverse-it clinical study on totum-63 to reduce type 2 diabetes risk factors

Regulatory news: valbiotis (paris:alval) (fr0013254851 - alval, pea/sme eligible) a research & development company committed to scientific innovat

BCPC Ratings Summary

BCPC Quant Ranking